These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26173007)

  • 21. Relative efficiency and sample size for cluster randomized trials with variable cluster sizes.
    You Z; Williams OD; Aban I; Kabagambe EK; Tiwari HK; Cutter G
    Clin Trials; 2011 Feb; 8(1):27-36. PubMed ID: 21163852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calculating sample size in trials using historical controls.
    Zhang S; Cao J; Ahn C
    Clin Trials; 2010 Aug; 7(4):343-53. PubMed ID: 20573638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finding Alternatives to the Dogma of Power Based Sample Size Calculation: Is a Fixed Sample Size Prospective Meta-Experiment a Potential Alternative?
    Tavernier E; Trinquart L; Giraudeau B
    PLoS One; 2016; 11(6):e0158604. PubMed ID: 27362939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Internal pilots for observational studies.
    Gurka MJ; Coffey CS; Gurka KK
    Biom J; 2010 Oct; 52(5):590-603. PubMed ID: 20857422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size requirement to detect an intervention effect at the end of follow-up in a longitudinal cluster randomized trial.
    Heo M; Kim Y; Xue X; Kim MY
    Stat Med; 2010 Feb; 29(3):382-90. PubMed ID: 20014353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size considerations for historical control studies with survival outcomes.
    Zhu H; Zhang S; Ahn C
    J Biopharm Stat; 2016; 26(4):657-71. PubMed ID: 26098200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical power for analyses of changes in randomized controlled trials.
    Tu YK; Blance A; Clerehugh V; Gilthorpe MS
    J Dent Res; 2005 Mar; 84(3):283-7. PubMed ID: 15723872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements.
    Hernández AV; Steyerberg EW; Habbema JD
    J Clin Epidemiol; 2004 May; 57(5):454-60. PubMed ID: 15196615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinded sample size re-estimation in a comparative diagnostic accuracy study.
    Stark M; Hesse M; Brannath W; Zapf A
    BMC Med Res Methodol; 2022 Apr; 22(1):115. PubMed ID: 35439947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generalized F test and generalized deviance test in two-way ANOVA models for randomized trials.
    Shen J; He X
    J Biopharm Stat; 2014; 24(3):523-34. PubMed ID: 24697334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reporting of sample size calculation in randomised controlled trials: review.
    Charles P; Giraudeau B; Dechartres A; Baron G; Ravaud P
    BMJ; 2009 May; 338():b1732. PubMed ID: 19435763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-stage sample size re-estimation based on a nuisance parameter: a review.
    Proschan MA
    J Biopharm Stat; 2005; 15(4):559-74. PubMed ID: 16022163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caution regarding the choice of standard deviations to guide sample size calculations in clinical trials.
    Chen H; Zhang N; Lu X; Chen S
    Clin Trials; 2013 Aug; 10(4):522-9. PubMed ID: 23794405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.